Title |
Rituximab for thyroid‐associated ophthalmopathy
|
---|---|
Published in |
Cochrane database of systematic reviews, May 2013
|
DOI | 10.1002/14651858.cd009226.pub2 |
Pubmed ID | |
Authors |
Neda Minakaran, Daniel G Ezra |
Abstract |
Thyroid associated ophthalmopathy (TAO) is the most frequent extrathyroidal manifestation of Graves' disease, affecting up to 50% of patients, and has a great impact on quality of life. Rituximab is a human/murine chimeric monoclonal antibody that targets CD20, a transmembrane protein expressed on the surface of pre-B and mature B lymphocytes, but not on stem cells, pro-B lymphocytes or plasma cells. Preliminary work has shown that blocking the CD20 receptor on B-lymphocytes with rituximab affects the clinical course of TAO, by reducing inflammation and the degree of proptosis. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 50% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | <1% |
Colombia | 1 | <1% |
Unknown | 103 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 14% |
Student > Master | 14 | 13% |
Other | 9 | 9% |
Student > Bachelor | 8 | 8% |
Student > Ph. D. Student | 7 | 7% |
Other | 16 | 15% |
Unknown | 36 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 39 | 37% |
Nursing and Health Professions | 9 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 2% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 10 | 10% |
Unknown | 38 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2013.
All research outputs
#14,841,711
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#9,909
of 11,499 outputs
Outputs of similar age
#109,870
of 207,187 outputs
Outputs of similar age from Cochrane database of systematic reviews
#221
of 267 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,187 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 267 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.